Sonoma Pharmaceuticals, Inc.

NasdaqCM:SNOA Stock Report

Market Cap: US$5.8m

Sonoma Pharmaceuticals Management

Management criteria checks 4/4

Sonoma Pharmaceuticals' CEO is Amy Trombly, appointed in Sep 2019, has a tenure of 6.83 years. total yearly compensation is $597.08K, comprised of 54.4% salary and 45.6% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $9.29K. The average tenure of the management team and the board of directors is 3.1 years and 4 years respectively.

Key information

Amy Trombly

Chief executive officer

US$597.1k

Total compensation

CEO salary percentage54.43%
CEO tenure6.8yrs
CEO ownership0.2%
Management average tenure3.1yrs
Board average tenure4yrs

Recent management updates

Recent updates

Analysis Article • Jan 14

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) is...
Analysis Article • Sep 18

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Screens Well But There Might Be A Catch

Sonoma Pharmaceuticals, Inc.'s ( NASDAQ:SNOA ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...
Analysis Article • Apr 26

A Piece Of The Puzzle Missing From Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) 35% Share Price Climb

Despite an already strong run, Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) shares have been powering on, with a gain...
Analysis Article • Mar 08

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 25% Lower

The Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Oct 17

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Stock's 43% Dive Might Signal An Opportunity But It Requires Some Scrutiny

To the annoyance of some shareholders, Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) shares are down a considerable 43...
Analysis Article • Aug 27

Market Cool On Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues Pushing Shares 33% Lower

Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) shares have retraced a considerable 33% in the last month, reversing a...
Analysis Article • Jul 12

The Market Lifts Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Shares 75% But It Can Do More

Despite an already strong run, Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) shares have been powering on, with a gain...
Analysis Article • May 26

Investors Aren't Entirely Convinced By Sonoma Pharmaceuticals, Inc.'s (NASDAQ:SNOA) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 0.3x Sonoma Pharmaceuticals, Inc. ( NASDAQ:SNOA ) is...
Seeking Alpha • Aug 11

Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.99M

Sonoma Pharmaceuticals press release (NASDAQ:SNOA): Q1 GAAP EPS of -$0.29. Revenue of $3.99M (+8.4% Y/Y).
Analysis Article • Sep 30

Does Sonoma Pharmaceuticals (NASDAQ:SNOA) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

CEO Compensation Analysis

How has Amy Trombly's remuneration changed compared to Sonoma Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$3m

Dec 31 2025n/an/a

-US$3m

Sep 30 2025n/an/a

-US$3m

Jun 30 2025n/an/a

-US$4m

Mar 31 2025US$597kUS$325k

-US$3m

Dec 31 2024n/an/a

-US$4m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$5m

Mar 31 2024US$727kUS$325k

-US$5m

Dec 31 2023n/an/a

-US$5m

Sep 30 2023n/an/a

-US$6m

Jun 30 2023n/an/a

-US$6m

Mar 31 2023US$560kUS$319k

-US$5m

Dec 31 2022n/an/a

-US$7m

Sep 30 2022n/an/a

-US$6m

Jun 30 2022n/an/a

-US$5m

Mar 31 2022US$643kUS$318k

-US$5m

Dec 31 2021n/an/a

-US$6m

Sep 30 2021n/an/a

-US$5m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021US$580kUS$300k

-US$5m

Dec 31 2020n/an/a

-US$3m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$5m

Mar 31 2020US$386kUS$153k

-US$4m

Compensation vs Market: Amy's total compensation ($USD597.08K) is about average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Amy's compensation has been consistent with company performance over the past year.

CEO

Amy Trombly (58 yo)

6.8yrs
Tenure
US$597,076
Compensation

Ms. Amy M. Trombly, Esq., JD, has been Chief Executive Officer of Sonoma Pharmaceuticals, Inc. since September 27, 2019 and serves as its President and also serves as its Director since July 22, 2022. She...

Leadership Team

NamePositionTenureCompensationOwnership
Amy Trombly
CEO, President & Director6.8yrsUS$597.08k0.16%
$ 9.3k
Jerome Dvonch
Chief Financial Officer3.3yrsUS$357.53k0.088%
$ 5.1k
Arturo Angel
Senior Vice President of Regulatoryless than a yearno datano data
John Poggetto
Controller3yrsUS$479.59kno data
3.1yrs
Average Tenure
58yo
Average Age

Experienced Management: SNOA's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Amy Trombly
CEO, President & Director4yrsUS$597.08k0.16%
$ 9.3k
John McLaughlin
Lead Independent Director13.3yrsUS$82.09k0.0056%
$ 326.6
Philippe Weigerstorfer
Independent Director7.8yrsUS$64.59k0.0026%
$ 151.1
Vanessa Jacoby
Independent Directorless than a yearno datano data
Hye Chung
Scientific Advisory Board2.9yrsno datano data
4.0yrs
Average Tenure
67yo
Average Age

Experienced Board: SNOA's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 14:27
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sonoma Pharmaceuticals, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jack WallaceSidoti & Company, LLC
David LavigneTrickle Research